CDKN2A and central nervous system cancer: The most recent grading system of gliomas has integrated the mutation status of key encoding genes prompting a ground-breaking change in the context of glioma diagnosis and treatment [1, 2] with further molecular stratification achieved by determining CDKN2A/B status [3].